title: A high level of TM4SF5 is associated with human esophageal cancer progression and poor patient survival.
abstract: OBJECTIVE
  We investigated expression of TM4SF5 and its involvement in human esophageal cancer (HEC).
  
  
  METHODS
  We analyzed TM4SF5 expression in normal esophageal epithelial cells (HEEC), in four HEC cell lines, and in 20 HEC clinical tissue samples and matched nontumor samples. The effect of TM4SF5 on HEC cell proliferation and metastasis and invasion was assessed, and the relationship between TM4SF5 and integrin β1 was determined. Finally, TM4SF5 and integrin β1 expression were further examined by use of immunohistochemistry (IHC) and tissue microarray analysis, and the prognostic use of TM4SF5 and integrin β1 in HEC was evaluated.
  
  
  RESULTS
  TM4SF5 was more highly expressed in HEC cells and in HEC tissues than in HEEC and matched nontumor tissues. Down-regulation of TM4SF5 in KYSE150 cells reduced cell proliferation and metastasis and invasion whereas metastasis and invasion by KYSE510 increased after TM4SF5 cDNA transfection. In HEC cells, TM4SF5 formed a complex with integrin β1, and interference with integrin β1 in KYSE510-TM4SF5 cells markedly inhibited cell invasion on laminin 5. Our findings also showed that TM4SF5 and integrin β1 overexpression correlated with low differentiation and high stage (p<0.05, respectively). Postoperative 5-year overall survival of patients with TM4SF5low and/or integrin β1low was higher than for patients with TM4SF5high and/or integrin β1high. Multivariate analysis demonstrated that TM4SF5 and integrin β1 co-overexpression was an independent prognostic marker for HEC.
  
  
  CONCLUSIONS
  TM4SF5 is positively associated with HEC invasiveness. The combination of TM4SF5 with integrin β1 could potentially serve as a novel marker for predicting HEC prognosis.
authors: Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, No. 1, Minde Road, Nanchang, 330006, Jiangxi Province, People's Republic of China.
authors: Yong-bing
authors: YB
authors: Wu
authors: You-sheng
authors: YS
authors: Huang
authors: Ya-ping
authors: YP
authors: Xu
authors: Yu-fang
authors: YF
authors: Sun
authors: Dong-liang
authors: DL
authors: Yu
authors: Xiao-qiang
authors: XQ
authors: Zhang
authors: Xiang
authors: X
authors: Long
authors: Shu-qiang
authors: SQ
authors: Zhu
authors: Jiang-liang
authors: JL
authors: Zhou
authors: Jian-jun
authors: JJ
authors: Xu
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism; D002277:Carcinoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D016022:Case-Control Studies; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002681:China / Q000453:epidemiology; D018450:Disease Progression; D004938:Esophageal Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D039641:Integrin beta Chains / Q000378:metabolism; D008297:Male; D008565:Membrane Proteins / Q000096:biosynthesis / Q000378:metabolism*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D010641:Phenotype; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; D039641:Integrin beta Chains; D008565:Membrane Proteins; C111029:TM4SF5 protein, human
references: Am J Gastroenterol. 2001 Dec;96(12):3457-8
references: 11774983
references: Trends Biochem Sci. 2003 Feb;28(2):106-12
references: 12575999
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Mol Cancer Ther. 2009 Sep;8(9):2635-44
references: 19723887
references: J Clin Invest. 2008 Apr;118(4):1354-66
references: 18357344
references: Biochem Biophys Res Commun. 2003 Apr 25;304(1):107-12
references: 12705892
references: Lancet Oncol. 2005 Nov;6(11):864-70
references: 16257794
references: Trends Cell Biol. 2009 Sep;19(9):434-46
references: 19709882
references: Clin Cancer Res. 2005 Apr 15;11(8):2947-53
references: 15837746
references: Protein Sci. 2000 Aug;9(8):1594-600
references: 10975581
references: Front Biosci (Landmark Ed). 2011 Jan 01;16:1752-8
references: 21196261
references: Gastroenterology. 2011 May;140(5):1629-41.e15
references: 21320503
references: PLoS One. 2011;6(9):e24901
references: 21961047
references: Cancer. 2010 Dec 1;116(23):5440-51
references: 20715158
references: PLoS One. 2012;7(3):e32775
references: 22427881
references: Cell Signal. 2003 Jun;15(6):559-64
references: 12681443
references: BMC Cancer. 2008 Sep 08;8:254
references: 18778486
references: J Cell Sci. 2003 Nov 15;116(Pt 22):4557-66
references: 14576349
references: Clin Exp Metastasis. 2011 Mar;28(3):261-70
references: 21184145
references: Carcinogenesis. 2009 Nov;30(11):1872-9
references: 19789264
references: Nat Rev Mol Cell Biol. 2005 Oct;6(10):801-11
references: 16314869
references: Hepatology. 2009 Apr;49(4):1316-25
references: 19177595
references: Clin Cancer Res. 2001 Nov;7(11):3519-25
references: 11705871
references: J Cell Biochem. 2010 Sep 1;111(1):59-66
references: 20506553
references: Hepatology. 2009 Feb;49(2):491-503
references: 19065669
references: CA Cancer J Clin. 2012 Jul-Aug;62(4):220-41
references: 22700443
references: Nat Rev Immunol. 2005 Feb;5(2):136-48
references: 15688041
references: Nat Rev Drug Discov. 2008 Sep;7(9):747-58
references: 18758472
references: Cancer. 2003 Apr 1;97(7):1616-23
references: 12655517